Vicapsys Life Sciences, Inc. (OTCPK: VICP)
Health Care · Biotechnology · US
$—
— today · — 1Y
Vicapsys Life Sciences, Inc. (OTCPK: VICP) operates in the Biotechnology industry within the Health Care sector. The company is valued at $46.94M and employs 2 people.
trading between 0.15 and 1.75.
Tweenvest scores Vicapsys Life Sciences, Inc. across four factors: quality 7/100. Its strongest factor is quality.
VICP price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $46.94M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.04
- Dividend yield
- —
- Beta (5Y)
- 424,349.76
- 52-week high
- $1.75
- 52-week low
- $0.15
- Avg volume (3M)
- —
- Shares outstanding
- 32.37M
- Employees
- 2
- Next earnings
- —
About Vicapsys Life Sciences, Inc.
Vicapsys Life Sciences, Inc. is primarily focused on bringing its exclusive VICAPSYN product to market, guiding it through development and commercialization. This product's intended application is within the field of transplantation, specifically for various transplant therapies and associated stem-cell uses. Additionally, the company is advancing the development of VYBRIN, a compound based on CXCL12. VYBRIN is being investigated for multiple purposes: preventing the formation of post-surgical adhesions following abdominal operations, coating implantable medical devices and other implants to inhibit fibrosis, and promoting wound healing, with a particular emphasis on diabetic ulcers. The firm, originally incorporated in 1997, transitioned its name from Phage Therapeutics International, Inc. to Vicapsys Life Sciences, Inc. in September 2017. Its operations are headquartered in Suwanee, Georgia.
- ISIN
- US92560A1060
- Founded
- 1997
- Listed since
- Feb 23, 1998
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.